Highlights d SPOP targets NANOG for degradation d Cancer-associated SPOP mutants lost the ability to degrade NANOG d NANOG stability is regulated by AMPK-BRAF-mediated phosphorylation d SPOP represses prostate cancer stemness via targeting NANOG SUMMARY NANOG is an essential transcriptional factor for the maintenance of embryonic stem cells (ESCs) and cancer stem cells (CSCs) in prostate cancer (PCa). However, the regulation mechanism of NANOG protein stability in cancer progression is still elusive.
In Brief
Wang et al. uncover a regulation mechanism by which NANOG stability, which is involved in the regulation of the stem-like characteristics of prostate cancer cells, is dictated by SPOPmediated degradation and is controlled by AMPK-BRAF-mediated phosphorylation of NANOG at Ser68.
INTRODUCTION
Most cancers have a small population of cells with stem celllike properties, termed as cancer stem cells (CSCs) that are capable of self-renewal and tumor-initiation (O'Brien et al., 2007; Patrawala et al., 2006; Singh et al., 2003) . Moreover, CSCs express pluripotency-related transcription factors of embryonic stem cells (ESCs), such as NANOG, OCT3/4, and SOX2 (Pece et al., 2010; Wong et al., 2008; Chambers and Tomlinson, 2009 ). The expression levels of these pluripotency transcriptional factors in cancers are tightly related to the development and progression of various cancers (Po et al., 2010; Suvà et al., 2013; Boumahdi et al., 2014) . PCa is one of the most common cancers in the world and the second leading cause of cancer-related deaths in men (Siegel et al., 2013) . Accumulating evidence indicates that the presence of CSCs is responsible for PCa initiation, progression and chemotherapy resistance (Jeter et al., 2011; Liu et al., 2010b) . Therefore, indepth understanding of the molecular underpinnings in PCa stem cell-like traits may shed light on the development of CSC-specific targeted therapy for PCa.
NANOG, an ESC transcription factor, maintains the selfrenewal and pluripotency of ESCs (Chambers et al., 2003; Mitsui et al., 2003) . NANOG is highly expressed in various cancers and plays a pleiotropic role in the tumorigenesis cascade, such as chemotherapy and radiation resistance, metabolism reprogramming and CSC population modulation (Santaliz-Ruiz et al., 2014; Chen et al., 2016) . Additionally, NANOG is a critical regulator for PCa progression (Ugolkov et al., 2011) , and its overexpression promotes the tumorigenesis in both androgen-sensitive and androgen-insensitive PCa cells (Zhang et al., 2014a) , indicative of poor prognosis (Mathieu et al., 2011; Miyazawa et al., 2014) . It has been reported that PCa cells are endowed with the stem-like properties by NANOG expression, especially under the stabilized and accumulated condition (Jeter et al., 2011; Kawamura et al., 2015) . However, the regulatory mechanism of NANOG stability in cancers remains unclear.
The ubiquitin-proteasome system (UPS) is one of the key pathways that regulate stem cell differentiation and function (Buckley et al., 2012) . Speckle-type POZ protein (SPOP) is a protein possessing the bric-a-brac-tramtrack-broad/poxvirus and zinc finger (BTB/POZ) domain, an adaptor for the E3 ubiquitin ligase Cullin3 (Zhuang et al., 2009) . SPOP gene mutation is highly relevant to human PCa, with a mutation rate of 10% to 15% (Cancer Genome Atlas Research, 2015) . SPOP can flexibly degrade various protein substrates such as androgen receptor (AR) Geng et al., 2014) , steroid receptor coactivator 3 (Li et al., 2011) , DEK, TRIM24 (Theurillat et al., 2014) , BRD4 (Janouskova et al., 2017; Dai et al., 2017; Zhang et al., 2017) , PD-L1 (Zhang et al., 2018) and ERG An et al., 2015) and thus regulate the proliferation and invasion of PCa. However, Developmental Cell 48, 345-360, February 11, 2019 ª 2018 Elsevier Inc. 345 the role of SPOP in mediating the stemness and pluripotency of PCa stem cells and ESCs remains largely unknown. In this study, we report that SPOP inhibits the self-renewal and stem-like characteristics of PCa via the ubiquitin-dependent degradation of NANOG. The cancer-associated NANOG S68Y mutant is refractory for SPOP-mediated degradation since NANOG Ser68 is required for the direct interaction between SPOP and NANOG. In parallel, AMPK activation promotes the NANOG degradation by blocking the binding of NANOG to BRAF that phosphorylates NANOG at Ser68. Thus, our study uncovers a de novo regulation mechanism of NANOG stability dictated by SPOP-induced degradation, which is abrogated by the phosphorylation of NANOG at Ser68 and thereby acts synergistically with the AMPK-BRAF signaling axis.
RESULTS

NANOG Is Degraded by SPOP
NANOG is often expressed in CSCs (Miyazawa et al., 2014; Jeter et al., 2009 ) and its expression is intimately correlated to poor prognosis in human PCa. Our study indicated that NANOG is a short-lived protein. Treatment with the proteasome inhibitor MG132 dramatically increased the protein level and prolonged the half-life of NANOG (Figures S1A and S1B). Similar results were obtained with the treatment of MLN4924 (Figures S1A and S1B), a potent inhibitor of Cullin-RING ligases by depressing the NEDD8-activating enzyme (NAE) (Ohh et al., 2002) , suggesting that NANOG is targeted for degradation through a Cullin E3 ubiquitin-ligase-mediated UPS pathway. To search for the Cullin-dependent E3 ligase that targets NANOG for degradation, we screened various dominant-negative forms of Cullins (dnCuls) together with the co-expression of NANOG. Our data showed that the dnCul3, but not other dnCuls, significantly stabilized NANOG (Figures 1A and S1C) . We further demonstrated that the depletion of Cullin3, but not other Cullins, markedly increased protein level of NANOG in DU145 PCa cells (Figures 1B and 1C) . Together, these data indicate that Cullin3 E3 ligase is involved in the control of NANOG degradation in PCa cells.
To identify the adaptor of Cullin3 that determines NANOG degradation, we analyzed the protein sequence of NANOG and revealed that NANOG contains an evolutionarily conserved SPOP-binding consensus motif (F-p-S-S/T-S/T; F, nonpolar residues; p, polar residues) (Zhuang et al., 2009 ) using online software (http://elm.eu.org/) ( Figure 1D ). We therefore examined whether NANOG is a potential substrate of SPOP. To this end, we co-expressed NANOG with SPOP in HEK293T cells and examined the protein level of NANOG. We found that co-expression of SPOP significantly shortened the half-life of NANOG (Figures S1D and S1E) . Moreover, both the protein level and the half-life of endogenous NANOG protein were significantly increased upon SPOP depletion in PCa cells and mouse ESCs (mESCs) (Figures 1E, S1F, and S1G). To further confirm this result, we generated two SPOP-deficient DU145 cell lines. Our data showed that the half-life of NANOG is significantly prolonged in SPOP-deficient DU145 cells ( Figure 1F ), indicating that NANOG is targeted for degradation by SPOP.
Next, we tested whether SPOP targets NANOG for ubiquitination. Our data showed that co-expression of SPOP significantly promoted NANOG ubiquitination in HEK293T cells ( Figure 1G ). In addition, depletion of SPOP markedly decreased NANOG ubiquitination in DU145 cells ( Figure 1H ). Moreover, Cul3-SPOP complex promoted the ubiquitination of NANOG in vitro (Figure S1H) . Deletion of the BTB domain in SPOP, which is required for its interaction with Cul3, failed to target NANOG for ubiquitination ( Figure S1H ), supporting an important role of Cullin3 enzyme activity in SPOP-mediated ubiquitination of NANOG.
Furthermore, we examined whether NANOG is a binding partner of SPOP. Our data indicated that SPOP specifically interacts with NANOG but not other stem cell transcriptional factors, including OCT4, SOX2, and KLF4 ( Figure 1I ). Notably, the interaction between endogenous SPOP and NANOG could be readily (C) DU145 cells were transfected with control siRNA or three independent Cul3-specific siRNAs. The endogenous NANOG were analyzed by WB. (D) Comparison of putative SPOP binding site in NANOG with the SPOP-binding consensus (SBC) motif defined in the known SPOP substrates. (E) PC3 cells were transfected with the indicated siRNA. The endogenous NANOG were analyzed by WB. (F) DU145 SPOP wild-type (WT) or KO cell lines were constructed by the lenti-CRISPR system; cells were treated with cycloheximide (CHX,10 mg/mL) for indicated times. Protein levels of NANOG and SPOP were analyzed by WB. (G) FLAG-NANOG, HA-SPOP, and His-ubiquitin were co-expressed in HEK293T cells. After treatment with MG132 (10 mM) for 6 hr, the nickel-nitrilotriacetic acid (Ni-NTA) ubiquitination assay was performed and analyzed by WB. (H) DU145 cells were transfected with the indicated siRNA and constructs for 3 days, the cells were treated with MG132 (5 mM) for 12 hr, cell lysate was immunoprecipitated (IP) with anti-NANOG antibody, and the ubiquitination of NANOG was detected by WB using the anti-His antibody. (I) FLAG-SPOP and indicated HA-tag plasmids were co-expressed in HEK293T cells. Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (J) DU145 cell lysates were prepared for coIP with SPOP antibody and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (K) E14 mESCs cell lysates were prepared for coIP with SPOP antibody and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (L) Representative sphere images from each condition of DU145 cells. Scale bar, 200 mm. (M) Indicated retrovirus infected DU145 tumor spheres were dissociated, and equal numbers of cells were passaged for three generations. Spheres counts are normalized to the first-generation scrambled short hairpin RNA (shRNA) spheres. Data are means ± SEM (n = 3). **p < 0.01 versus control shRNA (shCon) (Student's t test). (N and O) Growth of DU145 cell-(N) and 22RV1 cell-(O) derived tumors in nude mice infected with retrovirus expressing indicated shRNAs of three different cell densities. Frequency of CSCs is estimated as per extreme limiting dilution analysis (ELDA) calculating website, and p value represents overall test for differences in stem cell frequencies between the two groups; 1/1 in SPOP shRNA tumors means stem cell frequency (100%); *p < 0.05, ***p < 0.001 versus negative control (NC). detected in PCa cells (Figures 1J and S1I) and E14 mESCs (Figure 1K) . Moreover, our data showed that NANOG specifically interacts with SPOP but not other Cullin3-based E3 ligase adaptor proteins ( Figure S1J ). These results together indicate that SPOP is the adaptor responsible for interacting with NANOG and targeting it for ubiquitination by Cullin3 E3 ubiquitin ligase complex.
SPOP Represses Stem-Cell-like Properties via Its Regulation of NANOG Stability NANOG expression in PCa is closely correlated to CSC characteristics, we thus examined whether SPOP can regulate CSClike properties by targeting NANOG for degradation. To this end, we examined the effect of SPOP on the oncosphere-forming capacity of PCa cells, which is a standard for the measurement of CSC functions (Zhang et al., 2010) . The number of oncospheres formed over multiple passages represents the self-renewal activity, while the size of sphere indicates cell proliferation capability (Dontu et al., 2004) . Our data showed that compared to control cells infected with empty vector, both AR-negative DU145 and AR-positive 22RV1 cells lacking SPOP had a progressive increase in self-renewal capacity and the ability to form daughter spheres. Notably, simultaneous depletion of NANOG abolished the phenotype induced by SPOP depletion ( Figures 1L, 1M , S1L, and S1M). Moreover, SPOP knockout (KO) DU145 cells also showed an increased capability of forming oncospheres ( Figure S1K ). We further investigated whether SPOP can affect the tumor progression via its mediation of NANOG degradation using a nude mouse xenograft model. Our data showed that depletion of SPOP in AR-negative DU145 and AR-positive 22RV1 PCa cells significantly promoted tumor growth, whereas simultaneous depletion of NANOG abolished such phenotype induced by SPOP depletion (Figures S1N and S1O ). Furthermore, SPOP-depleted oncospheres developed more tumors, while simultaneous knockdown of NANOG abolished the phenotype derived from SPOP depletion ( Figures 1N and 1O ). Moreover, our data showed that knockdown of NANOG greatly reduced the ability of tumor formation when examined by the injection of as few as 1,000 oncospheres into nude mice ( Figures 1N,  1O , S1N, and S1O).
To further examine the role of SPOP in CSC function, we performed a clonal serial in vivo repopulation assay, which is a widely accepted functional assay to examine the self-renewal capacity of maintaining the long-term clonal growth of CSCs (Kreso and Dick, 2014) . Our data from triplicate experiments of serial transplantation showed that depletion of SPOP in both AR-negative DU145 and AR-positive 22RV1 PCa cells elevated the in vivo cell renewal efficacy in a NANOG-dependent manner ( Figures 1N, 1O , S1N, and S1O). These data together indicated that SPOP negatively regulates PCa stem cells maintenance in a NANOG-dependent manner and confirmed that regulation of PCa stem cells properties by SPOP-mediated NANOG degradation is independent of AR.
PCa-Associated SPOP Mutants Cannot Target NANOG for Degradation SPOP contains a MATH domain that is responsible for the substrate binding and a BTB domain that is required for its interaction with Cul3 (Zhuang et al., 2009) (Figure 2A ). Next, we determined the molecular basis of the interaction between NANOG and SPOP. Our data showed that WT SPOP directly interacted with NANOG, whereas the absence of the MATH domain completely abrogated the binding in vitro and in vivo (Figures 2B and S2A) . While deletion of BTB domain in SPOP also reduced the binding to its substrate, the plausible explanation is that the dimerization of SPOP through its BTB domain is required for sufficient interaction with substrates (Marzahn (B) HA-NANOG and indicated FLAG-tag SPOP plasmids were co-expressed in HEK293T cells. Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (C) FLAG-NANOG and HA-SPOP or mutants were co-expressed in HEK293T cells; protein levels of NANOG and SPOP were analyzed by WB. (D) FLAG-NANOG, HA-SPOP, or mutants and His-ubiquitin were co-expressed in HEK293T cells. After treatment with MG132 (10 mM) for 6 hr, the Ni-NTA ubiquitination assay was performed and analyzed by WB. (E) FLAG-NANOG and indicated HA-tag SPOP plasmids were co-expressed in HEK293T cells. Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (F) FLAG-NANOG was co-expressed in HEK293T cells with indicated HA-tag SPOP plasmids. After treating cells with CHX (10 mg/mL) for indicated time intervals, protein levels of NANOG and SPOP were analyzed by WB. (G) The NANOG protein abundance in (F) was quantified by ImageJ and plotted as indicated. (H) FLAG-NANOG, HA-SPOP or mutants and His-ubiquitin were co-expressed in HEK293T cells. After treatment with MG132 (10 mM) for 6 hr, the Ni-NTA ubiquitination assay was performed and analyzed by WB. (I) DU145 cells were infected with lentivirus expressed SPOP or F133L mutants; then the cells were treated with MG132 (10 mM) for 6 hr, cell lysate was IP with anti-NANOG antibody, and the ubiquitination of NANOG was detected by WB using the anti-ubiquitin (Ub) antibody. (J) Representative sphere images from each condition of DU145 cells. Scale bar, 200 mm. (K) Frequency of tumor spheres formed from DU145 cells in (J). Sphere counts are normalized to mock infected spheres. Data are means ± SEM (n = 3). **p < 0.01 versus empty vector (EV); ## p < 0.01 versus WT (Student's t test). (L) Representative sphere images from each condition of DU145 cells. Scale bar, 200 mm. (M) Indicated lentivirus infected DU145 tumor spheres were dissociated, and equal numbers of cells were passaged for three generations. Spheres counts are normalized to the first-generation scrambled shRNA spheres. Data are means ± SEM (n = 3). *p < 0.05, **p < 0.01 versus vector (Student's t test). (N) AP staining after 48 hr SPOP or SPOP mutant overexpression in E14 mESCs cells (left) and the expression of SPOP or its mutants and NANOG protein are shown (right). (O) Percentage of undifferentiated colonies counted in (N). Data are means ± SEM (n = 3). ## p < 0.01 versus EV; **p < 0.01 versus WT (Student's t test). (P) Immunofluorescent staining analysis for lentivirus expressed SPOP or mutants (green) and endogenous NANOG (red) in E14 mESCs cells. Scale bar, 100 mm. Zhang et al., 2014b) . Furthermore, our data showed that deletion of either the MATH domain or BTB domain abolished the SPOP-mediated NANOG degradation and ubiquitination ( Figures 2C and 2D ), while overexpression of SPOP, but not its deletion mutants (DBTB or DMATH) in E14 mESCs, led to a loss of mESC morphology and reduced AP staining ( Figures  S2B-S2D ).
Importantly, various somatic mutations have been identified in the MATH domain of SPOP in PCa tissues. Notably, these PCa-associated SPOP mutations, such as Y87C/N, F102C, and F133L/V, mainly occur on the amino acid residues located on the surface of the substrate-binding pocket of the MATH domain and thus lose the ability to bind and degrade its substrates (Barbieri et al., 2012; Blattner et al., 2014; Zhuang et al., 2009) . Our data indicate that these PCa-associated SPOP mutants are unable to interact with NANOG ( Figure 2E ). Consistently, ectopic expression of these PCa-associated SPOP mutants failed to degrade NANOG (Figures 2F and 2G) . Moreover, these mutants were incapable of promoting NANOG ubiquitination ( Figures 2H and 2I ). Functionally, the mutants (Y87C and F133L) failed to inhibit the sphere formation of PCa cells ( Figures 2J and 2K ). Besides, our data showed that cells ectopically expressing NANOG exhibited a great potential to form more and larger spheres than control samples, while such an effect was inhibited by WT-SPOP, but not its F133L mutant, in both DU145 and 22RV1 cells for three consecutive generations ( Figures 2L, 2M , S2E, and S2F). Furthermore, expression of WT-SPOP, but not its mutants including Y87C and F133L, impaired the stemness of mESCs ( Figures 2N  and 2P ).
To examine whether the mutation of SPOP is correlated to aberrant NANOG-mediated gene expression in PCa, we analyzed the gene-expression-based signatures from human clinical specimens with high expression levels of NANOG versus SPOP mutation. By two-class unpaired significance analysis of microarray data obtained from tumor and normal samples with or without SPOP mutation, as well as the patient cases with a high expression of NANOG from TCGA database, we observed an intimate correlation between the enhanced gene expression of mutant SPOP and a high level of NANOG in tumors (fold change > 2; q < 0.05) ( Figure S2G ). More importantly, our analysis demonstrated that 1,815 genes, including 756 upregulated genes and 1,059 downregulated genes, are affected by SPOP mutations and the high expression level of NANOG, emphasizing the crucial roles of both SPOP and NANOG in cancer progression (Figures S2H and S2I) . Indeed, the selected ones from the aforementioned 1,815 genes were influenced by the expression of NANOG ( Figures S2J and S2K ). Together, these data indicate that SPOP mutation affects the NANOG-regulated gene expression in PCa cells.
Identification of the SPOP-Binding Consensus Motif in NANOG
NANOG contains a conserved putative SPOP binding consensus (SBC) motif 66 PDSST 70 at its N terminus ( Figure 3A ). We then examined whether the putative SBC motif is involved in the interaction between SPOP and NANOG. Our data showed that deletion of the putative SBC motif (DPDSST) completely abolished the binding between NANOG and SPOP in vivo and in vitro (Figures 3B and 3C) . Moreover, deletion of the NANOG SBC motif dramatically prolonged its half-life (Figures S3A and S3B) and increased its transcriptional activity ( Figure S3C ). Importantly, SPOP was unable to promote the ubiquitination and degradation of the SBC-deleted NANOG mutant ( Figures 3D and 3F) . These data indicate that the SBC motif 66 PDSST 70 of NANOG is essential for its interaction with SPOP and resultant SPOP-mediated NANOG degradation.
We next explored whether the residues located in the SBC motif involve the interaction between NANOG and SPOP. The simultaneous replacement of Ser68, Ser69, or Thr70 with Ala (3A) in NANOG completely abolished its binding to SPOP (Figure 3B) . We also generated a series of NANOG point mutations, including S65A, P66A, D67A, S68A, S69A, T70A, S71A, and P72A and detected their interaction with SPOP. Co-immunoprecipitation (coIP) assays showed that D67A and S68A, but not other mutants, failed to interact with SPOP ( Figure 3G ). Consistent with these results, SPOP did not promote the degradation of NANOG-D67A and S68A mutants ( Figures 3H and 3J ). Moreover, data from the biotin-labeled peptide pull-down assay showed that SPOP bound to the peptide containing 66 PDSST 70 but not the mutated 66 PDAST 70 motif of NANOG ( Figure 3K ). These data together indicate that the SBC motif of NANOG, especially D67 and S68 residues, are essential for SPOP-mediated NANOG degradation.
Cancer-Associated NANOG Mutation within the SBC Motif Is Resistant to SPOP-Mediated Degradation
Our data showed that the SBC motif is essential for NANOG stability, we thus analyzed whether there is any mutation at the SBC motif of NANOG in cancers. Interestingly, a Ser68Tyr (S68Y) mutation in the SBC motif of NANOG was identified in endometrium carcinoma tissues by analyzing TCGA and COSMIC databases (https://cancer.sanger.ac.uk/cosmic/) (Figure 4A) . Through computational modeling analyses, we found that the amino acid sequence 66 PDSST 70 of NANOG binds to an extended groove in the MATH domain of SPOP ( Figure S4A ). However, the cancer-associated mutation 66 PDYST 70 in the NANOG mutant increased steric hindrance and impaired its interaction with SPOP ( Figures S4B) , suggesting that the cancer-associated mutant S68Y may affect the interaction between NANOG and SPOP.
To confirm this result, we examined the interaction between NANOG S68Y and SPOP. Our data showed that the NANOG S68Y mutant almost completely lost the ability to interact with SPOP ( Figure 4B ). Moreover, SPOP bound to the peptide motif of WT-NANOG containing 66 PDSST 70 , but not the point-mutated one within the sequence of 66 PDYST 70 ( Figure 4C ). Furthermore, SPOP promoted the degradation of WT-NANOG but not NANOG-S68Y ( Figures 4D-4F ). Consistently, SPOP promoted the ubiquitination of NANOG-WT but not NANOG-S68Y (Figure 4G) . Also, the NANOG S68Y mutant exhibited an increased transcriptional activity compared with that of WT-NANOG ( Figure S4C ).
Next, we examined whether NANOG-S68Y mutant regulates the function of CSCs. Sphere formation assays indicated that overexpression of NANOG-WT or NANOG S68Y significantly increased the efficacy of sphere formation ( Figures 4H and 4I) .
In contrast, co-expression of SPOP dramatically reduced the sphere-formation activity of NANOG-WT, but not that of the NANOG S68Y mutant ( Figures 4H and 4I ). In addition, SPOP inhibited the effect of WT-NANOG but not the NANOG SBCdeleted or S68Y mutants on migration and proliferation of PCa cells ( Figures S4D-S4F ). Subcutaneous injection of DU145 cells expressing the NANOG S68Y mutant into nude mice promoted tumor growth even under the condition of SPOP overexpression ( Figures 4J and 4K ). Together, these data indicate that NANOG-bearing mutations within the SBC motif are oncogenic and resistant to SPOP-mediated degradation.
Phosphorylation of NANOG at Ser68 Blocks Its Degradation by SPOP
Although our data identified that cancer-associated Ser68 mutation of NANOG abolished SPOP-mediated degradation, the mutation frequency of NANOG Ser68 is very low by our analysis from TCGA database. This triggered our exploration of other (B) FLAG-SPOP and indicated HA-tag NANOG plasmids were co-expressed in HEK293T cells (3A: S68A, S69A, T70A). Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (C) GST and GST-SPOP proteins were purified from E. coli and incubated with NANOG or PDSST deletion protein IP from HEK293T cells. The products of a pulldown assay were analyzed by WB. (D) FLAG-NANOG, HA-SPOP, and His-ubiquitin were co-expressed in HEK293T cells. After treatment with MG132 (10 mM) for 6 hr, the Ni-NTA ubiquitination assay was performed and analyzed by WB.
(E) FLAG-NANOG or PDSST deletion mutant was co-expressed in HEK293T cells with HA-SPOP. After treating cells with CHX (10 mg/mL) for indicated time intervals, protein levels of NANOG and SPOP were analyzed by WB.
(F) The NANOG protein abundance in (E) was quantified by ImageJ and plotted as indicated.
(G) HA-SPOP and indicated FLAG-tag NANOG plasmids were co-expressed in HEK293T cells. Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting.
(H) Ectopically expressed SPOP promotes protein degradation of exogenous WT-NANOG but not D67A or S68A mutants. 293T cells were transfected with indicated constructs for 24 hr followed by WB.
(I) FLAG-NANOG or mutants were co-expressed in HEK293T cells with HA-SPOP. After treating cells with CHX (10 mg/mL) for indicated time intervals, protein levels of NANOG and SPOP were analyzed by WB.
(J) The NANOG protein abundance in (I) was quantified by ImageJ and plotted as indicated.
(K) Binding was examined using biotinylated peptide pull-down assay and analyzed using WB.
possible mechanisms in mediating the stability regulation of NANOG. A pervious study showed that NANOG could be phosphorylated at Ser68 using high-resolution mass spectrometry (Brumbaugh et al., 2014) . To investigate whether the phosphorylation of Ser68 affects its interaction with SPOP, we con-structed a phosphorylation-mimic mutant of NANOG, S68D ( Figure 5A ). Our data indicated that the S68D mutant lost the ability to interact with SPOP ( Figure 5B ). Moreover, SPOP could not promote the degradation of NANOG S68D (Figures S5A-S5C) .
Our data from a peptide pull-down assay showed that SPOP (B) HA-SPOP was co-expressed with FLAG-NANOG or mutations in HEK293T cells. Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting.
(legend continued on next page)
bound to the peptide of 66 PDSST 70 in WT-NANOG but not the phosphorylated peptide of 66 PDS(P)ST 70 at Ser68 ( Figure S5D ), suggesting that the phosphorylation of NANOG at Ser68 blocked its interaction with SPOP. To further investigate the mechanism underlying NANOG Ser68 phosphorylation, we generated an antibody that could specifically recognize the Ser68-phosphorylated NANOG (p-S68 NANOG). Our data clearly showed that the antibody specifically targeted to Ser68-phosphorylated NANOG since it did not recognize the NANOG peptide mutated at Ser68 ( Figure S5E ).
AMPK Attenuates the Phosphorylation of NANOG at Ser68
Next, we aimed to identify the protein kinase that involves the phosphorylation of NANOG at Ser68. Since the phosphorylation of Ser68 may affect the protein stability of NANOG, it is a reasonable assumption that the kinases involved in the phosphorylation of NANOG should affect NANOG protein stability. To this end, we generated a cell line that is stably expressing NanoLuc-NANOG fusion protein and screened 244 kinase inhibitors by monitoring the NanoLuc activity. Our data showed that treatment of MG132 or MLN4924 efficiently increased the NanoLuc activity, indicating that this assay could identify the unique compound that affects NANOG stability ( Figure S5F) . Surprisingly, we found that the NanoLuc activity was significantly increased with the treatment of compound C (dorsomorphin), a specific inhibitor of AMPK ( Figure S5F ), suggesting that compound C may have an important effect on the stability of NANOG. Furthermore, the effect of compound C on NANOG stability was confirmed by western blotting (Figures 5C, 5D , S5G, and S5H). Importantly, we found that the regulatory role of compound C on NANOG stability is dependent on the presence of SPOP ( Figures 5C and 5D ). To further confirm that AMPK is involved in the regulation of NANOG stability, we expressed NANOG in AMPKa1/a2 À/À MEF cells and evaluated the half-life of NANOG. Our data clearly demonstrated that the half-life of NANOG was significantly prolonged in AMPKa1/a2 À/À MEF cells compared to that of WT MEFs. However, compound C failed to stabilize NANOG in AMPKa1/a2 À/À MEF cells ( Figures 5E and 5F) .
We therefore examined whether the activation of AMPK could promote NANOG degradation. To this end, 2-DG, a glucose molecule that can activate AMPK by increasing the cellular concentration of AMP/ATP was used . Defects in glucose metabolism create energy stress in cells and thereby activate AMPK kinase (Jones and Thompson, 2009) . Our data showed that the half-life of NANOG was significantly reduced upon the treatment of 2-DG or withdrawal of glucose ( Figures  S5I and S5J) . These data together indicate that AMPK is a negative regulator of NANOG stability.
Then we examined whether AMPK affects the phosphorylation of NANOG at Ser68. Our data showed that inhibition of AMPK with compound C significantly increased the phosphorylation of NANOG at Ser68 (Figures 5G and S5K ). On the other hand, AMPK activator AICAR reduced the phosphorylation of NANOG at Ser68 (Figures 5H and S5L) . Moreover, inhibition of AMPK abrogated the interaction between SPOP and NANOG, while activation of AMPK strengthened the association between SPOP and NANOG ( Figures 5I and S5M ).
Next, we examined whether AMPK affects NANOG stability dependent on the presence of SPOP. Our data indicated that inhibition of AMPK by compound C prolonged the half-life of NANOG in SPOP +/+ , but not SPOP À/À DU145 cells ( Figures 5C  and 5D ). Consistently, AMPK affected the ubiquitination of NANOG in SPOP +/+ , but not SPOP À/À cells (Figures 5J, 5K,  and S5N ). These data indicate that AMPK affects NANOG degradation and ubiquitination in a SPOP-dependent manner.
Functionally, we found that inhibition of AMPK dramatically increased the sphere-forming potential and cell proliferation in SPOP +/+ but not SPOP À/À DU145 cells ( Figures 5L and 5M ). On the other hand, the self-renewal capacity and proliferation of DU145 cells decreased upon the activation of AMPK ( Figures  5N and 5O ). Meanwhile, metformin (AMPK activator) reduced the (C) SPOP WT or KO DU145 cells were treated with compound C (6.6 mM) for 4 hr before performing the CHX (10 mg/mL) chase analysis. Expression levels of NANOG and SPOP were analyzed by WB. (D) The NANOG protein abundance in (C) was quantified by ImageJ and plotted as indicated. (E) AMPK WT and KO MEF cells were infected with lentivirus expressed NANOG, then treated with compound C (6.6 mM) for 4 hr before performing the CHX (10 mg/mL) chase analysis. (F) The NANOG protein abundance in (E) was quantified by ImageJ and plotted as indicated. (G) DU145 cells were treated with compound C (6.6 mM) for 4 hr; cell lysates were prepared for coIP with NANOG antibody and WB. (H) DU145 cells were treated with AICAR (2 mM) for 4 hr; cell lysates were prepared for coIP with NANOG antibody and WB. (I) DU145 cells were treated with DMSO or compound C (6.6 mM) for 4 hr; cell lysates were prepared for coIP with SPOP antibody, and the associated NANOG was analyzed by WB. (J and K) SPOP WT or KO DU145 cells were infected with lentivirus expressed His-Ub before being treated with compound C (6.6 mM) or 2-DG (25 mM) for 4 hr. cell lysates were IP by NANOG antibody and the ubiquitinated NANOG was analyzed by WB. (legend continued on next page) sphere formation of the DU145 cells expressing WT-NANOG, but not those overexpressing cancer-related NANOG S68Y mutant ( Figures 5P and 5Q) , which established the concept that AMPK regulates PCa stem cell traits in a SPOP-dependent manner. These results together suggest that AMPK affects the stemness of PCa cells via regulating NANOG phosphorylation at Ser68.
Phosphorylation of NANOG at Ser68 by BRAF As AMPK activation reduced the phosphorylation of NANOG at Ser68, it is unlikely that AMPK is the protein kinase that directly phosphorylates NANOG. To identify the protein kinase that is directly involved in the phosphorylation of NANOG at Ser68, we searched the online website (www.phosphonet.ca) and found that multiple kinases were potential candidates, including casein kinase, Raf Kinase, GSK-3b, and AKT. To determine which kinase is the right one, we co-expressed NANOG with these kinases, respectively, and the cells were treated with MG132 to avoid the influence from protein degradation. The phosphorylation of NANOG was examined using p-S68 antibody. Our data showed that BRAF kinase, but not other kinases listed above, specially increased the phosphorylation of NANOG at Ser68 (Figures 6A and 6B) . In parallel, treatment with BRAF kinase inhibitor AZ628 or LY03009120 inhibited the phosphorylation of NANOG Ser68 ( Figure S6A ). Kinase dead mutant K483M (BRAF) failed to promote the phosphorylation of NANOG at Ser68 ( Figure S6B ), suggesting that the kinase activity of BRAF is required for NANOG phosphorylation. Furthermore, we found that BRAF can bind to NANOG in cells ( Figure S6C ). Together, these data suggest that BRAF is a protein kinase that accounts for the phosphorylation of NANOG at Ser68. Next, we examined whether BRAF affects the protein stability of NANOG. Our data showed that the expression of BRAF, but not kinase dead mutant K483M, strongly increased the protein level and prolonged the half-life of NANOG ( Figures 5D and  6C ). On the other hand, knockdown of BRAF reduced the NANOG protein level ( Figure S6D ). The half-life of NANOG was also shortened with the treatment of BRAF inhibitor AZ628 and SB590885 (Figures S6F and S6G) .
Since BRAF can phosphorylate NANOG at Ser68, we examined whether BRAF affects the interaction between NANOG and SPOP. Our data showed that inhibition of BRAF increased the interaction between SPOP and NANOG ( Figure 6G ) and thereby promoted NANOG ubiquitination in DU145 cells (Figure S6E) . Consistently, the BRAF inhibitor had a minor effect on the half-life of NANOG in the SPOP À/À DU145 cells ( Figures  6E and 6F ), suggesting that BRAF affects NANOG stability in a SPOP-dependent manner.
Furthermore, in vitro phosphorylation assay demonstrated that BRAF could phosphorylate NANOG at Ser68 and the phosphorylation of NANOG at Ser68 prevented the interaction between SPOP and NANOG in vitro (Figures S6H and S6I ).
Phosphorylation of BRAF at Ser729 by AMPK Blocks Its
Interaction with NANOG We next examined whether the effect of AMPK on NANOG phosphorylation is dependent on BRAF. Our data showed that knockdown of BRAF abolished the inhibitory effect on the protein level of NANOG exerted by AMPK signaling (Figure 6H ), suggesting that AMPK may affect the NANOG stability via BRAF.
A previous report showed that AMPK phosphorylates BRAF at Ser729, disrupts the heterodimerization of BRAF with KSR1, and then prevents the paradoxical activation of MEK-ERK signaling (Shen et al., 2013) . We thus examined whether AMPK affects the function of NANOG by phosphorylating BRAF. To this end, we generated a phosphorylation-mimic mutant, BRAF Ser729D, and detected its interaction with NANOG. Our data showed that mutation of Ser729 to Asp (S729D) completely blocked the interaction between NANOG and BRAF ( Figure 6I ), suggesting that Ser729 is essential for its interaction with NANOG. Importantly, our data showed that mutation of BRAF at Ser729 lost the ability to stabilize NANOG in cells ( Figures 6J and 6K) .
Functionally, the BRAF inhibitor SB590885 impaired the sphere formation and cell proliferation of DU145 cells (Figures (C) FLAG-NANOG was co-expressed with FLAG-BRAF or K483M in HEK293T cells. After treating cells with CHX (10 mg/mL) for indicated time intervals, protein levels of NANOG and SPOP were analyzed by WB. (D) The NANOG protein abundance in (C) was quantified by ImageJ and plotted as indicated. (E) SPOP WT or KO DU145 cells were treated with SB590885 (10 mM) for 4 hr before performing the CHX (10 mg/mL) chase analysis. Expression levels of NANOG and SPOP were analyzed by WB. (F) The NANOG protein abundance in (E) was quantified by ImageJ and plotted as indicated. (G) DU145 cells were treated with DMSO or SB590885 (10 mM) for 4 hr, cell lysates were prepared for coIP with SPOP antibody, the associated NANOG was analyzed by WB. (H) DU145 cells were transfected with control siRNA or BRAF siRNA. After 72 hr, cells were treated with DMSO or compound C (6.6 mM) for 4 hr. Expression levels of NANOG were analyzed by WB. (I) FLAG-BRAFs and HA-NANOG were co-expressed in HEK293T cells. After 24 hr, cells were treated with metformin (2 mM) for 4 hr. Cell lysates were prepared for coIP and WB. Cells were treated with MG132 (10 mM) for 6 hr before harvesting. (J) FLAG-NANOG was co-expressed in HEK293T cells with indicated BRAF plasmids. After treating cells with CHX (10 mg/mL) for indicated time intervals, protein levels of NANOG were analyzed by WB. 6L, 6M, and S6J). Moreover, SB590885 led to a marked decrease in the sphere formation of DU145 cells expressing WT-NANOG, but not those expressing NANOG S68Y, indicating that BRAF largely governs PCa stem cell traits via the regulation of SPOP (Figures 6N and 6O) . Taken together, these results demonstrate that BRAF directly phosphorylates NANOG at Ser68 and increases the self-renewal capacity and cell proliferation of PCa cells by impairing the interaction between SPOP and NANOG.
Regulation of NANOG by SPOP in Clinical Applications
We next examined whether the regulation of NANOG by SPOP is correlated to PCa clinically. To this end, we analyzed the mutations of the MATH domain of SPOP in 33 PCa samples by Sanger sequencing and found that 7 of the 33 cases harbored SPOP mutations ( Figure S7A ). Interestingly, in addition to the well-characterized F133V, W131G, and R139K/T mutations, we identified a novel SPOP mutation, F104C, located in the MATH domain. Our data showed that the SPOP F104C mutant was also deficient in promoting NANOG degradation ( Figure S7B) .
The expression of NANOG in above-mentioned samples was also analyzed by immunohistochemistry (IHC). The specificity of NANOG antibody was examined by IHC assay in NANOG ectopically expressed HEK293T cells ( Figure S7C ). The staining of NANOG was scored as negative (0), weak (1), intermediate (2), or strong (3). We found that the protein expression of NANOG was higher in SPOP-mutated tumors than that of the SPOP-WT tumors (Figures 7A and 7B) . Moreover, we found that the percentage of cells with high expression of NANOG in SPOP mutated tissues was significantly more than that of WT tissues ( Figure 7C) . Surprisingly, we also found that NANOG was highly expressed in 34.6% of SPOP WT tissues ( Figure 7B ). As we found that SBC was essential for SPOP-mediated NANOG degradation, we examined whether NANOG is mutated in SBC in those tissues. However, we did not find mutations of NANOG at Ser68 or other sites via Sanger sequencing analysis (data not shown). We therefore examined whether the phosphorylation of NANOG at Ser68 is correlated to the expression level of NANOG in PCa. To this end, we analyzed the phosphorylation of S68 in WT-SPOP PCa tissues. The specificity of NANOG Ser68 phosphorylation antibody was examined by IHC assay in HEK293T cells expressing NANOG ectopically ( Figure S7D ). Interestingly, we found that the phosphorylated protein level of NANOG at Ser68 was closely correlated to the total protein level of NANOG in PCa specimens (Figures 7D and 7F) . These data support the notion that the stability of NANOG in PCa is controlled at multiple levels ( Figures 7G) .
DISCUSSION
In the current study, we demonstrated that the E3 ubiquitin ligase SPOP governs prostate CSC traits by modulating NANOG stability. Clinically, cancer-associated mutations in the MATH domain of SPOP disrupt the interaction between SPOP and NANOG, thereby preventing SPOP-mediated destruction of NANOG, stabilizing NANOG from AMPK-BRAF-signaling-axis-induced phosphorylation, and consequently promoting the maintenance of PCa stem-like cells. Our results offer fresh insight into CSC formation and show that SPOP, as a tumor suppressor, promotes NANOG ubiquitination and degradation in PCa cells and thus regulates PCa progression. AMPK, a master metabolic regulator, has emerged as a potential therapeutic target for various cancer treatments, such as breast cancer and PCa. AMPK activators such as AICAR and metformin have been shown to inhibit prostate cancer cell proliferation (Huang et al., 2008; Zakikhani et al., 2008) . A direct activator of AMPK inhibits PCa cell growth in the androgen-sensitive and castration-resistant PCa models (Zadra et al., 2014) . Metformin works together with chemotherapy to block tumor growth and prolong remission via targeting CSCs in breast cancer cell lines (Hirsch et al., 2009 ). However, the mechanism by which metformin targets CSCs remains unknown. In this study, we found that activation of AMPK attenuated NANOG phosphorylation at Ser68 and thus destabilized NANOG. Thus, our study suggests that AMPK activation may function as a novel therapeutic strategy for PCa treatments since it specifically targets at CSCs, thereby offering a very promising way to eliminate the tumor from the root.
BRAF is an oncogenic protein and its gain-of-function mutation has been demonstrated to be tightly correlated with cancer progression in various cancers, such as colon cancer and melanoma (Makrodouli et al., 2011; Lu et al., 2016 ). Gao's study showed that activation of B-Raf/Erk pathway can act synergistically to promote androgen independence in the context of the prostate microenvironment in vivo (Gao et al., 2006) . However, Raf signaling in prostate CSCs is not well understood yet. In our study, we found that BRAF can phosphorylate and stabilize NANOG to promote PCa stem cell-like traits. Although a low frequency of BRAF mutation was reported in PCa, our data showed that regulation of NANOG by BRAF is controlled by AMPK-mediated BRAF phosphorylation at Ser729. To further examine the role of Raf in PCa, we analyzed human epidemiological data using the PrognoScan database and found that higher BRAF expression predicted worse patient survival in human PCa (data not shown). Together, our study unveiled a novel mechanism by which BRAF regulates CSC activity via controlling NANOG stability.
As an essential E3 ubiquitin ligase, the role of SPOP in the maintenance of stem cell properties remains unknown. Our study presents the evidence showing that SPOP controls PCa stemness by degrading NANOG. We also found that overexpression of SPOP in mESCs results in the differentiation of mESCs. Our study discovered an unexplored area in regulating CSC characteristics, which not only contributes to a better understanding of tumorigenesis but also shed light on a novel strategy of anti-tumor therapeutics targeting at a thorough elimination of the ''seeds,'' CSCs.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: GlutaMAX, 0.1 mM non-essential amino acids (NEAA), 0.1 mM b-mercaptoethanol, 100 U/ml penicillin and 100 mg/ml streptomycin) supplemented with 1000 U/ml LIF and passaged every 3 days. Cells were cultured at 37 C supplied with 5% CO2. Transfection was performed by using calcium phosphate-DNA coprecipitation for HEK293T cells and using Lipofectamine 2000 for DU145, LNCaP, PC3 and E14 cells.
In Vivo Xenograft Assay All treatments were administered according to the guidelines of Institution Animal Care and Use Committee and all the protocols were approved by East China Normal University and Tongji University. Mice were caged in the groups of five in a laminar airflow cabinet under specific pathogen-free conditions, fed with sterilized food and water, and kept on a 12 hr light/dark cycle. Serial limiting dilution DU145 (AR -) or 22RV1 (AR + ) cells were admixed with Matrigel and injected into the backside of male 6-week-old BALB/cA nude mice. The animals were checked two to three times per week. Mean of primary, secondary and tertiary tumor volumes at 5 weeks. 
Human Prostate Tumor Tissue and IHC Staining
This study was approved by the ethical committee of Fudan University Shanghai Cancer Center (FUSCC), and each patient signed the consent form before participation (No.050432-4-1212B). Human prostate cancer tumor tissue arrays were provided by FUSCC. The arrays were stained by using the Histostain-plus IHC Kit (Miao Tong Biological Science and Technology Co.Ltd, Shanghai, China) as described previously (Liao et al., 2014) . Briefly, the tissue sections were deparaffinized and incubated in citrate buffer at 95 C for 40 mins for antigen retrieval and then incubated overnight at 4 C with the primary antibodies. After three times washing, tissue sections were incubated with biotinylated anti-rabbit IgG for 1 hr at room temperature and then washed three times, after which streptavidin-horseradish peroxidase conjugates were added and the slides were incubated for 45 mins. After three washes with PBS, DAB solution was added and the slides were counterstained with haematoxylin. The stained slides were examined under a microscope, and images were acquired. Staining intensity was scored in a blinded manner.
METHOD DETAILS
Alkaline Phosphatase (AP) Staining Alkaline Phosphatase staining was performed using a leukocyte AP kit (Sigma, catalog No 85L3R) according to the manufacturer's protocol. Briefly, the cultured cells were fixed with 4% paraformaldehyde (PFA) in PBS for 30 s and rinsed three times with PBS, then the cells were incubated at room temperature in the solution containing naphthol AS-BI phosphate and fresh fast red violet LB salt for 15 mins.
In Vitro Phosphorylation Assay Flag-BRAF was expressed in HEK293T cells and purified using M2 beads for immunoprecipitation and eluted using Flag peptide, purified Flag-BRAF was incubated with 0.5 mg His-NANOG in 50 ml of kinase buffer (25mM Tris-HCl (pH 7.5), 5 mM glycerophosphate, 10 mM MgCl 2 , 1mM DTT and 0.1 mM Na 3 VO 4 ) containing 100 mM ATP at 30 C for 1 hr. The reaction was terminated by the addition of 17 ml of 4XLaemmli SDS sample buffer. The reaction mixtures were boiled and separated by SDS-PAGE and phosphorylation NANOG was immunobloted by anti-pSer68-NANOG antibody.
Sphere Formation Assay
Oncosphere assays were performed as previously described (Liu et al., 2007) . Oncospheres were enriched from DU145 cells. Single-cell suspension of DU145 and PC3 cells (200 cells per well, repeat 10 holes in each group) were plated on 96-well ultralow Attachment Plates (Corning Incorporated, catalog number: 3474) and cultured in Dulbecco's Modified Eagle's Medium/F12 (Gibco) supplemented with 5 mg/ml insulin (Sigma), 20 ng/ml EGF (Sigma), 1:50 B27 (Gibco), 10 ng/ml bFGF, and 0.4% BSA for 10 days alone. Floating spheres that grew in 2 weeks were counted. Tumor spheres were visualized under phase contrast microscope, photographed and counted and represented graphically. Tumor spheres larger than 100 mm were counted, and the ''relative % of sphere'' represent the relative increase number of sphere per dish. Spheres were digested with trypsin 0.05% EDTA and filtered through a 40 mm filter.
